Tech Company Inital Public Offerings
Tarsus Pharmaceuticals IPO
Operating out of Irvine, Tarsus Pharmaceuticals is now a public company.
Transaction Overview
Company Name
Announced On
10/15/2020
Transaction Type
IPO
Amount
$88,000,000
Proceeds Purpose
Management says it will use the net proceeds from the IPO as follows:approximately $65.0 million to fund our development and regulatory approval of TP-03 for the treatment of Demodex blepharitis and to prepare for its commercial launch in the United States; andthe remaining proceeds to develop our product pipeline including TP-03 (for the treatment of MGD), TP-04, TP-05, and other general corporate purposes, which may include the hiring of additional personnel, capital expenditures and the costs of operating as a public company
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
19782 MacArthur Blvd. 285
Irvine, CA 92612
USA
Irvine, CA 92612
USA
Phone
Website
Email Address
Overview
Tarsus (Nasdaq: TARS) is a biopharmaceutical company headquartered in Irvine, California. Tarsus was founded in 2017 to bring innovative therapies to a range of diseases in need of better solutions, starting with Demodex blepharitis and eye care.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Michael Ackermann
Chief Executive Officer
Bobby Azamian
VP - Marketing
Maaza Martin
VP - Regulatory Affairs
Stephanie Baba
VP - Regulatory Affairs
Mark Holdbrook
Browse more venture capital transactions:
Prev: 10/15/2020: Fiveable venture capital transaction
Next: 10/15/2020: RayzeBio venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. VC investment data records reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs